The global Short-acting Recombinant Human Erythropoietin Drugs market size was valued at USD 9433.4 million in 2022 and is forecast to a readjusted size of USD 14300 million by 2029 with a CAGR of 6.1% during review period.
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.
The market for short-acting recombinant human erythropoietin drugs is currently in a steady growth phase, with its size gradually expanding, and sales continuing to rise. These drugs find extensive use in the treatment of anemia, especially in patients with chronic kidney disease, cancer chemotherapy recipients, and individuals requiring correction of hemoglobin levels pre-surgery. Future developments may include further expansion into additional clinical applications and more convenient administration routes, along with improved manufacturing techniques to meet the growing healthcare demands.
Report includes an overview of the development of the Short-acting Recombinant Human Erythropoietin Drugs industry chain, the market status of Anemia (Epoetin-alfa, Epoetin-beta), Kidney Disorders (Epoetin-alfa, Epoetin-beta), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Short-acting Recombinant Human Erythropoietin Drugs.
Regionally, the report analyzes the Short-acting Recombinant Human Erythropoietin Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Short-acting Recombinant Human Erythropoietin Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Short-acting Recombinant Human Erythropoietin Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Short-acting Recombinant Human Erythropoietin Drugs industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Epoetin-alfa, Epoetin-beta).
Industry Analysis: Report analyze the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Short-acting Recombinant Human Erythropoietin Drugs market.
Regional Analysis: The report involves examining the Short-acting Recombinant Human Erythropoietin Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behavior to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Short-acting Recombinant Human Erythropoietin Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Short-acting Recombinant Human Erythropoietin Drugs:
Company Analysis: Report covers individual Short-acting Recombinant Human Erythropoietin Drugs manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behavior, preferences, and attitudes towards Short-acting Recombinant Human Erythropoietin Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Anemia, Kidney Disorders).
Technology Analysis: Report covers specific technologies relevant to Short-acting Recombinant Human Erythropoietin Drugs. It assesses the current state, advancements, and potential future developments in Short-acting Recombinant Human Erythropoietin Drugs areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Short-acting Recombinant Human Erythropoietin Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Amgen
Johnson & Johnson
Roche
Kyowa Kirin
LG Chem
Daewoong Pharmaceutical
Wockhardt
CJ Healthcare
3SBio
Kexing Biopharm
Harbin Pharmaceutical Group
Beijing Four Rings Bio-Pharmaceutical
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others
Anemia
Kidney Disorders
Others
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Short-acting Recombinant Human Erythropoietin Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Short-acting Recombinant Human Erythropoietin Drugs, with price, sales, revenue and global market share of Short-acting Recombinant Human Erythropoietin Drugs from 2018 to 2023.
Chapter 3, the Short-acting Recombinant Human Erythropoietin Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Short-acting Recombinant Human Erythropoietin Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Short-acting Recombinant Human Erythropoietin Drugs market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Short-acting Recombinant Human Erythropoietin Drugs.
Chapter 14 and 15, to describe Short-acting Recombinant Human Erythropoietin Drugs sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Short-acting Recombinant Human Erythropoietin Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Epoetin-alfa
1.3.3 Epoetin-beta
1.3.4 Darbepoetin-alfa
1.3.5 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Anemia
1.4.3 Kidney Disorders
1.4.4 Others
1.5 Global Short-acting Recombinant Human Erythropoietin Drugs Market Size & Forecast
1.5.1 Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity (2018-2029)
1.5.3 Global Short-acting Recombinant Human Erythropoietin Drugs Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Amgen
2.1.1 Amgen Details
2.1.2 Amgen Major Business
2.1.3 Amgen Short-acting Recombinant Human Erythropoietin Drugs Product and Services
2.1.4 Amgen Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Amgen Recent Developments/Updates
2.2 Johnson & Johnson
2.2.1 Johnson & Johnson Details
2.2.2 Johnson & Johnson Major Business
2.2.3 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Product and Services
2.2.4 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Johnson & Johnson Recent Developments/Updates
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business
2.3.3 Roche Short-acting Recombinant Human Erythropoietin Drugs Product and Services
2.3.4 Roche Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Roche Recent Developments/Updates
2.4 Kyowa Kirin
2.4.1 Kyowa Kirin Details
2.4.2 Kyowa Kirin Major Business
2.4.3 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Product and Services
2.4.4 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Kyowa Kirin Recent Developments/Updates
2.5 LG Chem
2.5.1 LG Chem Details
2.5.2 LG Chem Major Business
2.5.3 LG Chem Short-acting Recombinant Human Erythropoietin Drugs Product and Services
2.5.4 LG Chem Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 LG Chem Recent Developments/Updates
2.6 Daewoong Pharmaceutical
2.6.1 Daewoong Pharmaceutical Details
2.6.2 Daewoong Pharmaceutical Major Business
2.6.3 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product and Services
2.6.4 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Daewoong Pharmaceutical Recent Developments/Updates
2.7 Wockhardt
2.7.1 Wockhardt Details
2.7.2 Wockhardt Major Business
2.7.3 Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Product and Services
2.7.4 Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Wockhardt Recent Developments/Updates
2.8 CJ Healthcare
2.8.1 CJ Healthcare Details
2.8.2 CJ Healthcare Major Business
2.8.3 CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Product and Services
2.8.4 CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 CJ Healthcare Recent Developments/Updates
2.9 3SBio
2.9.1 3SBio Details
2.9.2 3SBio Major Business
2.9.3 3SBio Short-acting Recombinant Human Erythropoietin Drugs Product and Services
2.9.4 3SBio Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 3SBio Recent Developments/Updates
2.10 Kexing Biopharm
2.10.1 Kexing Biopharm Details
2.10.2 Kexing Biopharm Major Business
2.10.3 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Product and Services
2.10.4 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Kexing Biopharm Recent Developments/Updates
2.11 Harbin Pharmaceutical Group
2.11.1 Harbin Pharmaceutical Group Details
2.11.2 Harbin Pharmaceutical Group Major Business
2.11.3 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Product and Services
2.11.4 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Harbin Pharmaceutical Group Recent Developments/Updates
2.12 Beijing Four Rings Bio-Pharmaceutical
2.12.1 Beijing Four Rings Bio-Pharmaceutical Details
2.12.2 Beijing Four Rings Bio-Pharmaceutical Major Business
2.12.3 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product and Services
2.12.4 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Beijing Four Rings Bio-Pharmaceutical Recent Developments/Updates
3 Competitive Environment: Short-acting Recombinant Human Erythropoietin Drugs by Manufacturer
3.1 Global Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Manufacturer (2018-2023)
3.2 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Manufacturer (2018-2023)
3.3 Global Short-acting Recombinant Human Erythropoietin Drugs Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Short-acting Recombinant Human Erythropoietin Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Short-acting Recombinant Human Erythropoietin Drugs Manufacturer Market Share in 2022
3.4.2 Top 6 Short-acting Recombinant Human Erythropoietin Drugs Manufacturer Market Share in 2022
3.5 Short-acting Recombinant Human Erythropoietin Drugs Market: Overall Company Footprint Analysis
3.5.1 Short-acting Recombinant Human Erythropoietin Drugs Market: Region Footprint
3.5.2 Short-acting Recombinant Human Erythropoietin Drugs Market: Company Product Type Footprint
3.5.3 Short-acting Recombinant Human Erythropoietin Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Short-acting Recombinant Human Erythropoietin Drugs Market Size by Region
4.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Region (2018-2029)
4.1.2 Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Region (2018-2029)
4.1.3 Global Short-acting Recombinant Human Erythropoietin Drugs Average Price by Region (2018-2029)
4.2 North America Short-acting Recombinant Human Erythropoietin Drugs Consumption Value (2018-2029)
4.3 Europe Short-acting Recombinant Human Erythropoietin Drugs Consumption Value (2018-2029)
4.4 Asia-Pacific Short-acting Recombinant Human Erythropoietin Drugs Consumption Value (2018-2029)
4.5 South America Short-acting Recombinant Human Erythropoietin Drugs Consumption Value (2018-2029)
4.6 Middle East and Africa Short-acting Recombinant Human Erythropoietin Drugs Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Type (2018-2029)
5.2 Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Type (2018-2029)
5.3 Global Short-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Application (2018-2029)
6.2 Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Application (2018-2029)
6.3 Global Short-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2018-2029)
7 North America
7.1 North America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Type (2018-2029)
7.2 North America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Application (2018-2029)
7.3 North America Short-acting Recombinant Human Erythropoietin Drugs Market Size by Country
7.3.1 North America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Country (2018-2029)
7.3.2 North America Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Type (2018-2029)
8.2 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Application (2018-2029)
8.3 Europe Short-acting Recombinant Human Erythropoietin Drugs Market Size by Country
8.3.1 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Country (2018-2029)
8.3.2 Europe Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Short-acting Recombinant Human Erythropoietin Drugs Market Size by Region
9.3.1 Asia-Pacific Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Type (2018-2029)
10.2 South America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Application (2018-2029)
10.3 South America Short-acting Recombinant Human Erythropoietin Drugs Market Size by Country
10.3.1 South America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Country (2018-2029)
10.3.2 South America Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Market Size by Country
11.3.1 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Short-acting Recombinant Human Erythropoietin Drugs Market Drivers
12.2 Short-acting Recombinant Human Erythropoietin Drugs Market Restraints
12.3 Short-acting Recombinant Human Erythropoietin Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Short-acting Recombinant Human Erythropoietin Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Short-acting Recombinant Human Erythropoietin Drugs
13.3 Short-acting Recombinant Human Erythropoietin Drugs Production Process
13.4 Short-acting Recombinant Human Erythropoietin Drugs Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Short-acting Recombinant Human Erythropoietin Drugs Typical Distributors
14.3 Short-acting Recombinant Human Erythropoietin Drugs Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Amgen Basic Information, Manufacturing Base and Competitors
Table 4. Amgen Major Business
Table 5. Amgen Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 6. Amgen Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Amgen Recent Developments/Updates
Table 8. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 9. Johnson & Johnson Major Business
Table 10. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 11. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Johnson & Johnson Recent Developments/Updates
Table 13. Roche Basic Information, Manufacturing Base and Competitors
Table 14. Roche Major Business
Table 15. Roche Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 16. Roche Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Roche Recent Developments/Updates
Table 18. Kyowa Kirin Basic Information, Manufacturing Base and Competitors
Table 19. Kyowa Kirin Major Business
Table 20. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 21. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Kyowa Kirin Recent Developments/Updates
Table 23. LG Chem Basic Information, Manufacturing Base and Competitors
Table 24. LG Chem Major Business
Table 25. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 26. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. LG Chem Recent Developments/Updates
Table 28. Daewoong Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 29. Daewoong Pharmaceutical Major Business
Table 30. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 31. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Daewoong Pharmaceutical Recent Developments/Updates
Table 33. Wockhardt Basic Information, Manufacturing Base and Competitors
Table 34. Wockhardt Major Business
Table 35. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 36. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Wockhardt Recent Developments/Updates
Table 38. CJ Healthcare Basic Information, Manufacturing Base and Competitors
Table 39. CJ Healthcare Major Business
Table 40. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 41. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. CJ Healthcare Recent Developments/Updates
Table 43. 3SBio Basic Information, Manufacturing Base and Competitors
Table 44. 3SBio Major Business
Table 45. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 46. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. 3SBio Recent Developments/Updates
Table 48. Kexing Biopharm Basic Information, Manufacturing Base and Competitors
Table 49. Kexing Biopharm Major Business
Table 50. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 51. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Kexing Biopharm Recent Developments/Updates
Table 53. Harbin Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 54. Harbin Pharmaceutical Group Major Business
Table 55. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 56. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Harbin Pharmaceutical Group Recent Developments/Updates
Table 58. Beijing Four Rings Bio-Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 59. Beijing Four Rings Bio-Pharmaceutical Major Business
Table 60. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 61. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Beijing Four Rings Bio-Pharmaceutical Recent Developments/Updates
Table 63. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 64. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Manufacturer (2018-2023) & (USD Million)
Table 65. Global Short-acting Recombinant Human Erythropoietin Drugs Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 66. Market Position of Manufacturers in Short-acting Recombinant Human Erythropoietin Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 67. Head Office and Short-acting Recombinant Human Erythropoietin Drugs Production Site of Key Manufacturer
Table 68. Short-acting Recombinant Human Erythropoietin Drugs Market: Company Product Type Footprint
Table 69. Short-acting Recombinant Human Erythropoietin Drugs Market: Company Product Application Footprint
Table 70. Short-acting Recombinant Human Erythropoietin Drugs New Market Entrants and Barriers to Market Entry
Table 71. Short-acting Recombinant Human Erythropoietin Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 72. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 73. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 74. Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 75. Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 76. Global Short-acting Recombinant Human Erythropoietin Drugs Average Price by Region (2018-2023) & (US$/Unit)
Table 77. Global Short-acting Recombinant Human Erythropoietin Drugs Average Price by Region (2024-2029) & (US$/Unit)
Table 78. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 79. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 80. Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 81. Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 82. Global Short-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2018-2023) & (US$/Unit)
Table 83. Global Short-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2024-2029) & (US$/Unit)
Table 84. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 85. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 86. Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Application (2018-2023) & (USD Million)
Table 87. Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Application (2024-2029) & (USD Million)
Table 88. Global Short-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2018-2023) & (US$/Unit)
Table 89. Global Short-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2024-2029) & (US$/Unit)
Table 90. North America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 91. North America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 92. North America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 93. North America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 94. North America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 95. North America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 96. North America Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 97. North America Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 98. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 99. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 100. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 101. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 102. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 103. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 104. Europe Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 105. Europe Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 106. Asia-Pacific Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 107. Asia-Pacific Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 108. Asia-Pacific Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 109. Asia-Pacific Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 110. Asia-Pacific Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 111. Asia-Pacific Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 112. Asia-Pacific Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 113. Asia-Pacific Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 114. South America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 115. South America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 116. South America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 117. South America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 118. South America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 119. South America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 120. South America Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 121. South America Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 122. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 123. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 124. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 125. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 126. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 127. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 128. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 129. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 130. Short-acting Recombinant Human Erythropoietin Drugs Raw Material
Table 131. Key Manufacturers of Short-acting Recombinant Human Erythropoietin Drugs Raw Materials
Table 132. Short-acting Recombinant Human Erythropoietin Drugs Typical Distributors
Table 133. Short-acting Recombinant Human Erythropoietin Drugs Typical Customers
List of Figures
Figure 1. Short-acting Recombinant Human Erythropoietin Drugs Picture
Figure 2. Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value Market Share by Type in 2022
Figure 4. Epoetin-alfa Examples
Figure 5. Epoetin-beta Examples
Figure 6. Darbepoetin-alfa Examples
Figure 7. Others Examples
Figure 8. Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 9. Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value Market Share by Application in 2022
Figure 10. Anemia Examples
Figure 11. Kidney Disorders Examples
Figure 12. Others Examples
Figure 13. Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity (2018-2029) & (K Units)
Figure 16. Global Short-acting Recombinant Human Erythropoietin Drugs Average Price (2018-2029) & (US$/Unit)
Figure 17. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity Market Share by Manufacturer in 2022
Figure 18. Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value Market Share by Manufacturer in 2022
Figure 19. Producer Shipments of Short-acting Recombinant Human Erythropoietin Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 20. Top 3 Short-acting Recombinant Human Erythropoietin Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Top 6 Short-acting Recombinant Human Erythropoietin Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 23. Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value Market Share by Region (2018-2029)
Figure 24. North America Short-acting Recombinant Human Erythropoietin Drugs Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Short-acting Recombinant Human Erythropoietin Drugs Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Short-acting Recombinant Human Erythropoietin Drugs Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Short-acting Recombinant Human Erythropoietin Drugs Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 30. Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value Market Share by Type (2018-2029)
Figure 31. Global Short-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2018-2029) & (US$/Unit)
Figure 32. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 33. Global Short-acting Recombinant Human Erythropoietin Drugs Consumption Value Market Share by Application (2018-2029)
Figure 34. Global Short-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2018-2029) & (US$/Unit)
Figure 35. North America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 36. North America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 37. North America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 38. North America Short-acting Recombinant Human Erythropoietin Drugs Consumption Value Market Share by Country (2018-2029)
Figure 39. United States Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Canada Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Mexico Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 43. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 44. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 45. Europe Short-acting Recombinant Human Erythropoietin Drugs Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. France Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. United Kingdom Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Russia Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Italy Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 53. Asia-Pacific Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 54. Asia-Pacific Short-acting Recombinant Human Erythropoietin Drugs Consumption Value Market Share by Region (2018-2029)
Figure 55. China Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Japan Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Korea Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. India Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Southeast Asia Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Australia Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. South America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 62. South America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 63. South America Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 64. South America Short-acting Recombinant Human Erythropoietin Drugs Consumption Value Market Share by Country (2018-2029)
Figure 65. Brazil Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Argentina Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 68. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 69. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 70. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Consumption Value Market Share by Region (2018-2029)
Figure 71. Turkey Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Egypt Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Saudi Arabia Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. South Africa Short-acting Recombinant Human Erythropoietin Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Short-acting Recombinant Human Erythropoietin Drugs Market Drivers
Figure 76. Short-acting Recombinant Human Erythropoietin Drugs Market Restraints
Figure 77. Short-acting Recombinant Human Erythropoietin Drugs Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Short-acting Recombinant Human Erythropoietin Drugs in 2022
Figure 80. Manufacturing Process Analysis of Short-acting Recombinant Human Erythropoietin Drugs
Figure 81. Short-acting Recombinant Human Erythropoietin Drugs Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
